Acute disseminated encephalomyelitis

Lore & Background

ADEM produces multiple inflammatory lesions in the brain and spinal cord, particularly in the white matter, including subcortical and central white matter, cortical gray-white junction, cerebellum, brainstem, and spinal cord. Symptoms begin abruptly, usually 1–3 weeks after infection, and include fever, headache, nausea, confusion, vision impairment, drowsiness, seizures, and coma, worsening rapidly over hours to days with average time to maximum severity about four and a half days.

Reader's Guide

ADEM is significant as a rare but serious autoimmune demyelinating condition that primarily affects children, with an average age of 5 to 8 years. Its distinction from multiple sclerosis lies in its typically monophasic course, rapid onset with fever, and potential for loss of consciousness or coma. The disease shows seasonal variation with higher incidence in winter and spring, likely coinciding with viral infections. While full recovery occurs in 50 to 75% of cases, mortality can reach 5%. The discovery of anti-MOG antibodies has linked ADEM to a broader category of anti-MOG associated encephalomyelitis, though not all cases test positive. Its legacy includes clarifying the spectrum of demyelinating diseases and the role of immune responses to infections and, rarely, vaccinations.

Did You Know?

• ADEM affects about 8 per 1,000,000 people per year.
• The average age of onset is 5 to 8 years old.
• Full recovery is seen in 50 to 75% of cases.
• Multiple vaccines have been associated with ADEM in medical literature, including the Semple rabies vaccine, as well as others such as measles, mumps, rubella, and influenza vaccines.

Pathophysiology and Clinical Presentation

ADEM is an autoimmune condition in which the body's immune system launches a sudden, widespread assault on the brain and spinal cord. The attack targets the myelin sheath—the protective insulation wrapping central nervous system nerves—ultimately destroying the white matter that depends on it. Inflammatory lesions cluster in the subcortical and central white matter, the cortical gray-white junction of both cerebral hemispheres, the cerebellum, brainstem, and spinal cord, though periventricular regions, thalami, and basal ganglia can also be involved.

Clinically, the disease strikes with abrupt onset and follows a monophasic trajectory. Symptoms typically emerge one to three weeks after a triggering event and escalate rapidly over hours to days, reaching peak severity in roughly four and a half days on average. The initial presentation often includes fever, headache, nausea, vomiting, confusion, visual disturbances, drowsiness, seizures, and in severe cases, coma. As the condition progresses, patients may develop hemiparesis, paraparesis, or cranial nerve palsies, reflecting the multifocal damage to neural pathways.

Triggers and Etiology

The precise mechanism behind ADEM remains tied to the anti-MOG antibody, a specificity originally identified in the context of multiple sclerosis research. In roughly two-thirds of affected individuals, a preceding antigenic challenge can be traced. A long list of viral agents has been implicated, including influenza, dengue, enterovirus, measles, mumps, rubella, varicella zoster, Epstein-Barr virus, cytomegalovirus, herpes simplex, hepatitis A, coxsackievirus, and notably SARS-CoV-2. Bacterial culprits such as Mycoplasma pneumoniae, Borrelia burgdorferi, Leptospira, and beta-hemolytic Streptococci have also been linked.

Vaccination has been a controversial trigger. The Semple rabies vaccine is the only one with proven causation, while numerous others—measles, mumps, rubella, pertussis, diphtheria, polio, and others—have been associated in small case series. However, large epidemiological studies of MMR and smallpox vaccines have failed to demonstrate elevated ADEM risk. The estimated upper-bound risk from measles vaccination sits at roughly 10 per million, far below the 1-in-1,000 risk posed by a natural measles infection. In exceedingly rare instances, ADEM has followed organ transplantation.

Distinguishing ADEM from Multiple Sclerosis

Because both conditions involve autoimmune destruction of myelin, ADEM has long been catalogued among the borderline diseases adjacent to multiple sclerosis. Yet several critical differences set them apart. ADEM predominantly strikes children, with the average age of onset hovering around five to eight years, whereas MS more commonly presents in young adults. Fever is a hallmark of the ADEM episode but is not a typical feature of MS relapses.

The most defining distinction lies in the disease course. ADEM is fundamentally monophasic—a single, acute flare-up—while MS is characterized by repeated relapses spread across years or decades. That said, up to one-quarter of ADEM patients experience a subsequent demyelinating episode, and the majority of those multiphasic presentations are now believed to represent MS rather than true recurrent ADEM. When genuine recurrence does occur, the condition is reclassified as multiphasic disseminated encephalomyelitis, or MDEM.

ADEM can also progress to loss of consciousness, coma, and even death, outcomes that are exceedingly rare in MS outside the most severe presentations. A fulminant adult course has also been described, underscoring that the two diseases, while related, follow distinctly different trajectories.

Epidemiology, Prognosis, and the COVID-19 Connection

ADEM is a rare condition, affecting approximately 8 in every million people annually. Although it can occur at any age, the bulk of reported cases cluster in children and adolescents, with males and females affected almost equally. A notable seasonal pattern emerges: incidence peaks during winter and spring months, a timing that aligns with the higher circulation of viral pathogens during those seasons.

Prognosis, while serious, is often favorable. Mortality can reach as high as 5 percent, yet between 50 and 75 percent of patients achieve full recovery, and survival rates climb to 70–90 percent when minor residual disability is included in the favorable category. The average recovery window from a flare-up spans one to six months.

The relationship between ADEM and SARS-CoV-2 has drawn particular attention. In documented cases, neurological symptoms were the predominant presentation and did not track with respiratory severity. Brain inflammation appears driven by an immune-mediated response rather than direct viral neurotropism. Neuroimaging revealed bilateral, relatively asymmetrical periventricular lesions with deep white matter involvement, sometimes extending into cortical gray-white junctions, thalami, basal ganglia, cerebellum, and brainstem. Hemorrhagic white matter lesions and clusters of macrophages associated with axonal injury further supported an acute demyelinating process.